Covance Co-Locates Facility for Increased Patient Exposure
LabCorp® announced that Covance Drug Development has relocated its clinical research unit in Dallas, TX, to a new, fit-for-purpose clinical research facility.
LabCorp® announced that Covance Drug Development has relocated its clinical research unit in Dallas, TX, to a new, fit-for-purpose clinical research facility. This unit opened earlier this month and has expanded from 72 to 100 medical beds. In addition, a LabCorp patient service center will be co-located in the CRU, at which patients will have an opportunity to learn more about volunteering and participating in early stage clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
